IntegraGen Announces Its Research Showing the Connection between miR-31-3p Expression and cetuximub efficacy in patients with KRAS wild-type metastatic colorectal cancer as published on Oncotarget

Recently, IntegraGen, a company that specializes in breaking down the human genome to in an effort to produce pertinent and easily interpretable data that can be used in both academic and commercial purposes announced that their findings from a study inquiring into miR-31-3p expression in cancerous tumor samples that were collected from patients who had been enrolled in the NEW EPOC clinical trial had been published online on Oncotarget. The title of the paper being “Association between miR-31-3p expression and cetuximub efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial”. The findings seemed to come to the conclusion that there is a connection between miR-31-3p expression and how effective the anti-EGFR treatment can be.

One of the co-authors of the study Professor John Bridgewater is a Medical Oncologist at University College London Cancer Institute. Prof. Bridgewater as one of the scientists who was heavily involved with the New EPOC Study said that the publication contains results showing that miR-31-3p expression levels in patients who have been diagnosed with RAS wild-type metastatic colorectal cancer can serve as a diagnostic tool that helps find patients who qualify for targeted anti-EGFR therapy.He further expressed his confidence that they will continue to further examine data from the New EPOC trial. This data is very important especially to clinicians as it provides the much needed additional understanding on customizing therapeutic approaches to improve treatment of patients who have come down with metastatic colorectal cancer.IntegraGen‘s Director of Molecular Diagnostics Yann Gaston-Mathé also said that the findings have given more credibility to the exercise of measuring miR-31-3p in cancerous tumors from patients who have been diagnosed with metastatic colorectal cancer.

Who is IntegraGen?

IntegraGen is an Evry Genopole based company that specializes in breaking down the human genome to in an effort to produce pertinent and easily interpretable data that can be used in both academic and private laboratories. By 2016, IntegraGen had generated over €6.0 million in revenues with a payroll of 38 employees. Its U.S. office is in Cambridge, Massachusetts.

About Oncotarget

Oncotarget is a free weekly peer-reviewed medical journal established in 2010 and published by Impact Journals. It covers research on all aspects of oncology. Oncotarget also includes articles on other subjects and fields of study in science and medicine such as Metabolism, Endocrinology, Neuroscience, the aging process, Microbiology, Cardiology, The Immunology System, Pharmacology Cell Biology, among others. Oncotarget is one of the most popular journals in the circles of Medicine and Science professionals as the source of up-to-the-minute news, research, and information on the aforementioned fields of study. This can be demonstrated by the simple fact that in the years 2015 and 2016, Oncotarget had an impact factor 5.008. Mikhail Blagosklonny a former professor at the Roswell Park Cancer Institute in New York and Andrei V. Gudkov of Roswell Park Cancer Institute are the editors-in-chief of Oncotarget. Roswell Park Cancer Institute is a cancer research and treatment center based Buffalo, New York founded by Dr. Roswell Park in 1898.